Diabetes increases the risk of cardiovascular disease; however, this risk is further increased as a result of other
factors. This observation is particularly relevant with regard to lipid abnormalities. Although diabetic dyslipidemia is
characterized by hypertriglyceridemia, low HDL-cholesterol, and small dense LDL particles, the main determinant of the
role of dyslipidemia in the prognosis of diabetics is LDL cholesterol. In recent years, LDL cholesterol targets have
become progressively lower, and most current recommendations establish an LDL cholesterol target of <70 mg/dL for
diabetics. This target can only be achieved using potent statins at adequate doses. Although it has been suggested that
statins may interfere with glycemic metabolism, the benefits of reducing LDL cholesterol by statins are much greater than
this possible deleterious effect.
Rosuvastatin is one of the most potent statins available. Several studies have shown that it effectively reduces LDL
cholesterol to recommended targets in diabetics. Moreover, rosuvastatin modestly increases HDL cholesterol and
decreases triglycerides. The risk of side effects is low, as is the risk of interactions with other drugs.
In this manuscript, the efficacy and safety profile of rosuvastatin in diabetic population is reviewed.
Keywords: Diabetes, efficacy, HDL-cholesterol, LDL cholesterol, lipid profile, lipids, rosuvastatin, safety, statins, total
cholesterol, treatment, triglycerides.
Rights & PermissionsPrintExport